CN100404533C - 奎宁环酰胺衍生物 - Google Patents

奎宁环酰胺衍生物 Download PDF

Info

Publication number
CN100404533C
CN100404533C CNB03820648XA CN03820648A CN100404533C CN 100404533 C CN100404533 C CN 100404533C CN B03820648X A CNB03820648X A CN B03820648XA CN 03820648 A CN03820648 A CN 03820648A CN 100404533 C CN100404533 C CN 100404533C
Authority
CN
China
Prior art keywords
group
hydroxy
compound
octane
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB03820648XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1678610A (zh
Inventor
M·普拉特基尼奥内斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almirall SA
Original Assignee
Almirall Prodesfarma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma AG filed Critical Almirall Prodesfarma AG
Publication of CN1678610A publication Critical patent/CN1678610A/zh
Application granted granted Critical
Publication of CN100404533C publication Critical patent/CN100404533C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB03820648XA 2002-07-02 2003-06-25 奎宁环酰胺衍生物 Expired - Fee Related CN100404533C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200201539 2002-07-02
ES200201539A ES2204295B1 (es) 2002-07-02 2002-07-02 Nuevos derivados de quinuclidina-amida.

Publications (2)

Publication Number Publication Date
CN1678610A CN1678610A (zh) 2005-10-05
CN100404533C true CN100404533C (zh) 2008-07-23

Family

ID=30011350

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03820648XA Expired - Fee Related CN100404533C (zh) 2002-07-02 2003-06-25 奎宁环酰胺衍生物

Country Status (24)

Country Link
US (2) US7488735B2 (https=)
EP (1) EP1519933B1 (https=)
JP (1) JP2005533826A (https=)
CN (1) CN100404533C (https=)
AR (1) AR040351A1 (https=)
AT (1) ATE467631T1 (https=)
AU (1) AU2003242757B2 (https=)
BR (1) BR0312216A (https=)
CA (1) CA2492535A1 (https=)
DE (1) DE60332534D1 (https=)
EC (1) ECSP045519A (https=)
ES (1) ES2204295B1 (https=)
IL (1) IL165923A (https=)
MX (1) MXPA04012271A (https=)
MY (1) MY130803A (https=)
NO (1) NO20050164L (https=)
NZ (1) NZ537341A (https=)
PE (1) PE20040644A1 (https=)
RU (1) RU2314306C2 (https=)
TW (1) TW200402420A (https=)
UA (1) UA80832C2 (https=)
UY (1) UY27870A1 (https=)
WO (1) WO2004005285A1 (https=)
ZA (1) ZA200410404B (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
PE20060259A1 (es) * 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.
JP4781362B2 (ja) * 2004-09-15 2011-09-28 書強 趙 ４級アンモニウム基を有するキヌクリジン化合物とその調製方法、およびアセチルコリン遮断剤としての用途
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
US9088384B2 (en) * 2005-10-27 2015-07-21 Qualcomm Incorporated Pilot symbol transmission in wireless communication systems
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (en) 2006-04-21 2013-09-18 Novartis AG Purine derivatives for use as adenosin A2A receptor agonists
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
ES2554646T3 (es) * 2007-02-23 2015-12-22 Theravance Biopharma R&D Ip, Llc Compuestos de difenilmetilo de amonio cuaternario, de utilidad como antagonistas de receptores muscarínicos
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
WO2009098455A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
CA2733449A1 (en) * 2008-08-12 2010-02-18 Astrazeneca Ab 2-hydroxy-ethanesulfonate salt
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CA2834467A1 (en) * 2011-04-29 2012-11-01 Chiesi Farmaceutici S.P.A. Alkaloid ester and carbamate derivatives and medicinal compositions thereof
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9056867B2 (en) 2011-09-16 2015-06-16 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
EP3023424B1 (en) * 2013-07-13 2019-02-27 Beijing Shuobai Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
US10100012B2 (en) * 2014-05-30 2018-10-16 Sphaera Pharma Pvt. Ltd. Compounds as anti-tubercular agents
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
CN110759904B (zh) * 2019-10-21 2023-03-14 河南科技大学 9r-酰氧基奎宁类衍生物及其制备方法、奎宁或其衍生物的应用、植物源杀虫剂
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2762796A (en) 1956-09-11 Iminodibenzyl derivative
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1246606A (en) 1969-04-28 1971-09-15 Starogardzkie Zakl Farma Dibenzo-azepine derivatives
IL72788A (en) 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
GB2225574B (en) 1987-12-24 1991-04-24 Wyeth John & Brother Ltd Heterocyclic compounds
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
GB9201751D0 (en) 1992-01-28 1992-03-11 Smithkline Beecham Plc Compounds
GB9202443D0 (en) 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
ATE205490T1 (de) 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate
AUPN862996A0 (en) 1996-03-13 1996-04-04 Fujisawa Pharmaceutical Co., Ltd. A novel substituted-acetamide compound
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
CZ294251B6 (cs) 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
IL156558A0 (en) 2000-12-28 2004-01-04 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
EP1461336B1 (en) 2001-12-20 2013-05-22 CHIESI FARMACEUTICI S.p.A. 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ATE378336T1 (de) 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004118A2 (en) * 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Quinuclidine derivatives and their use as muscarinic m3 receptor ligands

Also Published As

Publication number Publication date
ECSP045519A (es) 2005-03-10
ZA200410404B (en) 2005-09-05
WO2004005285A1 (en) 2004-01-15
MXPA04012271A (es) 2005-04-08
MY130803A (en) 2007-07-31
EP1519933B1 (en) 2010-05-12
IL165923A (en) 2010-06-30
NO20050164L (no) 2005-04-04
RU2314306C2 (ru) 2008-01-10
AU2003242757A1 (en) 2004-01-23
ATE467631T1 (de) 2010-05-15
US20060167042A1 (en) 2006-07-27
AR040351A1 (es) 2005-03-30
UY27870A1 (es) 2003-10-31
UA80832C2 (en) 2007-11-12
PE20040644A1 (es) 2004-09-18
BR0312216A (pt) 2005-04-12
AU2003242757B2 (en) 2009-01-08
DE60332534D1 (de) 2010-06-24
US20080234316A1 (en) 2008-09-25
US7488735B2 (en) 2009-02-10
US7718670B2 (en) 2010-05-18
NZ537341A (en) 2006-04-28
JP2005533826A (ja) 2005-11-10
RU2005102585A (ru) 2005-10-10
ES2204295B1 (es) 2005-08-01
CA2492535A1 (en) 2004-01-15
TW200402420A (en) 2004-02-16
IL165923A0 (en) 2006-01-15
ES2204295A1 (es) 2004-04-16
CN1678610A (zh) 2005-10-05
EP1519933A1 (en) 2005-04-06

Similar Documents

Publication Publication Date Title
CN100404533C (zh) 奎宁环酰胺衍生物
US7192978B2 (en) Pyrrolidinium derivatives
JP4295985B2 (ja) 新規なキヌクリジン誘導体およびそれを含む医薬組成物
KR100869722B1 (ko) 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
CN100363363C (zh) 奎宁环衍生物及含有相同化合物的药用组合物
KR20060109432A (ko) Ｎ-헤테로시클릴메틸벤즈아미드의 유도체, 그의 제조 방법및 치료에 있어서 그의 적용
RU2382041C2 (ru) Новые сложные эфиры кватернизованного хинуклидина
TWI304067B (en) Novel quinuclidine carbamate derivatives and medicinal compositions containing the same
KR20050024450A (ko) 신규한 퀴누클리딘 아미드 유도체
HK1098465B (en) Use of tricyclic compounds as glycine transport inhibitors
HK1142887B (en) Use of tricyclic compounds as glycine transport inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ALMILAR EXPERIMENTAL ROOM CO., LTD.

Free format text: FORMER OWNER: GRUPO FARMACEUTICO ALMIRALL

Effective date: 20081031

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20081031

Address after: Spain Barcelona

Patentee after: Laboratorios Almirall SA

Address before: Swiss Swiss

Patentee before: Almirall Prodesfarma AG

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080723

Termination date: 20110625